Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Federal Minister of Health tables the 2022 Annual Report of the Patented Medicine Prices Review Board | ||
By: PR Newswire Association LLC. - 16 Feb 2024 | Back to overview list |
|
OTTAWA, ON, Feb. 16, 2024 /CNW/ - The Honourable Mark Holland, Federal Minister of Health, today tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons. The 2022 Annual Report outlines trends in the prices and sales of patented medicines in Canada. Sales of patented medicines were $18.4 billion in 2022 and accounted for approximately 49% of the sales of all medicines in Canada. The report also sets out findings on spending on pharmaceutical research and development in Canada, as well as updated information on the PMPRB's price review and reporting activities in 2022. The PMPRB is an independent quasi-judicial body that protects the interests of Canadian consumers by ensuring the prices of patented medicines sold in Canada are not excessive, and provides stakeholders with pharmaceutical price, cost, and utilization information to help them make timely and knowledgeable pricing, purchasing, and reimbursement decisions. Quick Facts
Associated Links 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB) Follow us on X, formerly known as Twitter: @PMPRB_CEPMB SOURCE Patented Medicine Prices Review Board |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |